期刊文献+

糖耐量减低患者应用吡格列酮治疗前后血清C反应蛋白的变化 被引量:1

Changes in C-reactive Protein in Patients with Impaired Glucose Tolerance Treated with Pioglitazone
下载PDF
导出
摘要 目的观察盐酸吡格列酮治疗糖耐量减低(IGT)前后血清高敏C反应蛋白(hsCRP)的变化及其影响因素,探讨糖脂代谢与炎性因子的关系。方法采用随机平行对照方法将86例IGT患者随机分为盐酸吡格列酮组与对照组,进行为期12周的临床观察。结果吡格列酮治疗后患者hsCRP水平明显下降(P<0.01),而对照组无变化。结论IGT患者高血糖状态、胰岛素抵抗(IR)与炎症关系密切,吡格列酮治疗在改善糖脂代谢的同时,还具有明显的抗炎作用,使hsCRP水平明显下降。 Objective To observe the changes in serum high sensitivity C-reactive protein(hsCRP) in patients with impaired glucose tolerance after treatment with pioglitazone and investigate the relationship between inflammatory factors and metabolism of glucose and lipid. Methods A 12-week randomized, controlled study was performed to compare the effects of placebo and pioglitazone in 86 patients with IGT. Results A significant reduction in hsCRP level was observed during teatment with pioglitazone( P 〈 0.01 ), in the placebo treated patients the hsCRP level varied non-signifieantlyConclusion There is a close relationship among hyperglycemia, insulin resistance, and inflammation in patients with IGT,pioglitazoue not only has obvious anti-inflammatory actiou,but also can decrease the level of hsCRP besides the effect improving the glyeolipid metabolism.
出处 《医学综述》 2008年第3期472-474,共3页 Medical Recapitulate
关键词 糖尿病 吡格列酮 糖耐量减低 C反应蛋白 Diabetes Pioglitazone Impaired glucose tolerance C-reactive protein
  • 相关文献

参考文献10

二级参考文献49

  • 1Prandhan AD,Manson JE,Nader R,et al.C-reactive protein,interleukin-6,and risk of developing type 2 diabetes mellitus[J].JAMA,2001,286(3):327-334. 被引量:1
  • 2Reaven GM.Role of insulin insistance in human desease[J].Diabetes,1988,37(12):1595-1607. 被引量:1
  • 3Festa A,Dagostino RJ,Howard G,et al.Chronic subclinical inflammation as part of the insulin resistance syndrome:the Insulin Resistance Atherosclerosis Study (IRAS)[ J ].Circulation,2000,102(1):42-47. 被引量:1
  • 4Kriketos AD,Greenfield JR,Peakepw PW,et al.Inflammation,insulin resistance,and adiposity diabetic-a study of first-degree relative of type 2 diabetic subjects[J].Diabetes Care,2004,27(8):2033-2040. 被引量:1
  • 5Duclos TW.Function of c-reactive protein[J].Ann Med,2000,32(4):274-278. 被引量:1
  • 6Forhlich M,Imhof A,Berg G,et al.Association between Creaction protein and feature of the metabolic syndrome,a population-based study[J].Diabetes Care,2000,23(12):1835-1839. 被引量:1
  • 7Haffner SM.Insulin resistance,inflammation,and the prediabetic state[J].Am J Cardiol,2003,92(suppl 4):18-26. 被引量:1
  • 8BASTARD J P,PIERONI L,HAINQUE B.Relationship between plasma plasminogen activator inhibitor 1 and insulin resistance [J].Diabetes Metab Revs Rev,2000,16(3):192-201. 被引量:1
  • 9ASO Y,MATSUMOTO S,FUJIWARA Y,et al.Impaired fibrinolytic compensation for hypercoagulability in obese patients with type 2 diabetes:association with increased plasminogen activator inhibitor-1 [J].Metabolism,2002,51(4):471-476. 被引量:1
  • 10PICK J C,CROOK M A.Is type 2 diabetes mellitus a disease of the innate immune system?[J].Diabetologia,1998,41(10):1241-1248. 被引量:1

共引文献81

同被引文献2

引证文献1

二级引证文献2

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部